A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study

TitleA phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study
Publication TypeJournal Article
Year of Publication2008
AuthorsPignata, S, Breda, E, Scambia, G, Pisano, C, Zagonel, V, Lorusso, D, Greggi, S, De Vivo, R, Ferrandina, G, Gallo, C, Perrone, F
JournalCrit Rev Oncol Hematol
Volume66
Pagination229-36
Keywords80 and over Antineoplastic Agents/administration & dosage/therapeutic use/toxicity Antineoplastic Agents, Aged Aged, Phytogenic/administration & dosage/adverse effects/therapeutic use Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects/therapeutic use Carboplatin/*administration & dosage/adverse effects/therapeutic use Comorbidity Di
Abstract

BACKGROUND: Carboplatin/paclitaxel every 3 weeks is the standard for patients with ovarian cancer, but elderly patients frequently receive modified schedules or single agent chemotherapy to avoid toxicity. A phase II study was conducted to describe tolerability of a weekly schedule of both drugs in elderly patients. METHODS: Patients aged>or=70 years with stage IC-IV ovarian cancer, performance status